(VR-496) - 药物靶点：Cell adhesion molecules x HPSE_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Heparin inhalation

靶点

Cell adhesion molecules x HPSE

作用机制

细胞粘附分子抑制剂、乙酰肝素酶抑制剂、Inflammation mediators抑制剂(炎症介导素抑制剂)

治疗领域

免疫系统疾病遗传病与畸形消化系统疾病+ [2]

在研适应症-

非在研适应症

哮喘囊性纤维化慢性阻塞性肺疾病

原研机构

Vectura Group Ltd.

在研机构-

非在研机构

Vectura Group Ltd.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

4

项与 VR-496 相关的临床试验

ChiCTR2300077243 / Recruiting早期临床1期IIT

Effect of intravenous anesthesia and inhalation anesthesia on postoperative recovery quality of patients undergoing bariatric surgery

开始日期2023-11-02

申办/合作机构-

NCT04511923 / Unknown status临床1/2期

Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Respiratory Support in Ireland

The investigators present a randomised open label phase Ib/IIa trial of nebulised unfractionated heparin to evaluate the effect of nebulised unfractionated heparin on the procoagulant response in ICU patients with SARS-CoV-2 requiring advanced respiratory support. As this is one of the first studies of nebulised heparin in COVID 19 lung disease the investigators will assess safety as a co-primary outcome.

开始日期2020-12-23

申办/合作机构

University Hospital Galway

NCT03516656 / Completed早期临床1期IIT

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular surgery. Additionally, a pilot protocol has been developed to titrate these heparin infusions to ensure patients have sufficient VTE prophylaxis. All patients will be enrolled in the observational arm of the study and receive anti-Xa level monitoring. Patients with out-of-range anti-Xa levels will cross over to the interventional arm of the study and receive real time heparin infusion dose adjustments per the pilot protocol. The primary outcome measured will be the percentage of patients with anti-Xa levels in the target range of 0.1-0.35 IU/mL while on a heparin infusion at 10 units/kg/hour.

开始日期2018-03-23

申办/合作机构

University of Utah

100 项与 VR-496 相关的临床结果

登录后查看更多信息

100 项与 VR-496 相关的转化医学

登录后查看更多信息

100 项与 VR-496 相关的专利（医药）

登录后查看更多信息

8

项与 VR-496 相关的文献（医药）

2016-11-01·Depression and anxiety1区 · 医学

MID-PREGNANCY CORTICOTROPIN-RELEASING HORMONE LEVELS IN ASSOCIATION WITH POSTPARTUM DEPRESSIVE SYMPTOMS

1区 · 医学

Article

作者: Sundström Poromaa, Inger ; Olivier, Jocelien D. ; Sylvén, Sara ; Hellgren, Charlotte ; Comasco, Erika ; Schijven, Dick ; Chrousos, George P. ; Iliadis, Stavros I. ; Skalkidou, Alkistis

BACKGROUND:

Peripartum depression is a common cause of pregnancy- and postpartum-related morbidity. The production of corticotropin-releasing hormone (CRH) from the placenta alters the profile of hypothalamus-pituitary-adrenal axis hormones and may be associated with postpartum depression. The purpose of this study was to assess, in nondepressed pregnant women, the possible association between CRH levels in pregnancy and depressive symptoms postpartum.

METHODS:

A questionnaire containing demographic data and the Edinburgh Postnatal Depression Scale (EPDS) was filled in gestational weeks 17 and 32, and 6 week postpartum. Blood samples were collected in week 17 for assessment of CRH. A logistic regression model was constructed, using postpartum EPDS score as the dependent variable and log-transformed CRH levels as the independent variable. Confounding factors were included in the model. Subanalyses after exclusion of study subjects with preterm birth, newborns small for gestational age (SGA), and women on corticosteroids were performed.

RESULTS:

Five hundred thirty-five women without depressive symptoms during pregnancy were included. Logistic regression showed an association between high CRH levels in gestational week 17 and postpartum depressive symptoms, before and after controlling for several confounders (unadjusted OR = 1.11, 95% CI 1.01-1.22; adjusted OR = 1.13, 95% CI 1.02-1.26; per 0.1 unit increase in log CRH). Exclusion of women with preterm birth and newborns SGA as well as women who used inhalation corticosteroids during pregnancy did not alter the results.

CONCLUSIONS:

This study suggests an association between high CRH levels in gestational week 17 and the development of postpartum depressive symptoms, among women without depressive symptoms during pregnancy.

2015-06-01·The Journal of clinical endocrinology and metabolism2区 · 医学

Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis

2区 · 医学

Review

作者: Pereira, Alberto M. ; Dekkers, Olaf M. ; Broersen, Leonie H. A. ; Jørgensen, Jens Otto L.

Objective::

We aimed to estimate pooled percentages of patients with adrenal insufficiency after treatment with corticosteroids for various conditions in a meta-analysis. Secondly, we aimed to stratify the results by route of administration, disease, treatment dose, and duration.

Methods::

We searched seven electronic databases (PubMed, MEDLINE, EMBASE, COCHRANE, CENTRAL, Web of Science, and CINAHL/Academic Search Premier) in February 2014 to identify potentially relevant studies. Original articles testing adult corticosteroid users for adrenal insufficiency were eligible.

Results::

We included 74 articles with a total of 3753 participants. Stratified by administration form, percentages of patients with adrenal insufficiency ranged from 4.2% for nasal administration (95% confidence interval [CI], 0.5–28.9) to 52.2% for intra-articular administration (95% CI, 40.5–63.6). Stratified by disease, percentages ranged from 6.8% for asthma with inhalation corticosteroids only (95% CI, 3.8–12.0) to 60.0% for hematological malignancies (95% CI, 38.0–78.6). The risk also varied according to dose from 2.4% (95% CI, 0.6–9.3) (low dose) to 21.5% (95% CI, 12.0–35.5) (high dose), and according to treatment duration from 1.4% (95% CI, 0.3–7.4) (<28 d) to 27.4% (95% CI, 17.7–39.8) (>1 year) in asthma patients.

Conclusions::

1) Adrenal insufficiency after discontinuation of glucocorticoid occurs frequently; 2) there is no administration form, dosing, treatment duration, or underlying disease for which adrenal insufficiency can be excluded with certainty, although higher dose and longer use give the highest risk; 3) the threshold to test corticosteroid users for adrenal insufficiency should be low in clinical practice, especially for those patients with nonspecific symptoms after cessation.

2012-01-01·Journal of the Indian Society of Pedodontics and Preventive Dentistry

Effects of Asthma and Inhalation corticosteroids on the dental arch morphology in children

Article

作者: SS Kumar ; B Nandlal

BACKGROUND:

Hereditary, environmental and developmental factors play an important role in dentofacial development, as well as the initiation of malocclusion disorder. Allergic phenomenon such as asthma that induces an alternative mode of breathing in patients is a contributing factor in development of the dental arch.

AIM:

Our aim in this study was to evaluate the dentoalveolar morphology in asthmatic children and to analyze the effects of asthmatic medications on the dental arch.

SETTING AND DESIGN:

This study is centered on 44 asthmatic children aged between 6-12 years from J.S.S Hospital, Mysore. Selected variables from model analysis of the casts of the asthmatic group were subjected to comparison with those of the non-asthmatic group, which comprised of 44 non-asthmatic children. Selected parameters were arch width, arch length and palatal depth.

MATERIALS AND METHODS:

Impressions of upper and lower arches were made with rubber based impression material. A sliding digital caliper was used to measure the casts for arch width and arch length. A palatal depth gauge was used to measure the palatal depth.

STATISTICAL ANALYSIS:

Differences in arch widths, arch lengths and palatal depths between asthmatics and non-asthmatics groups were evaluated by independent sample t-tests. Chi-square test was applied to assess the frequency of occurrence of malocclusion in the asthmatic children.

RESULT:

The results obtained revealed that the arch length and palatal depth of asthmatic group had higher values compared to that of non-asthmatic groups for both age groups (6 to 8-year-old males and females, 10 to 12-year-old males and females). Inter molar width showed a significant lower value in asthmatics in the maxillary arches of 10 to 12-year-old females. Fifty percent of the asthmatic children aged 10 to 12-years had open-bite. Children under regular medication showed significant deviation in the dentoalveolar morphology as compared to those under irregular medication.

CONCLUSION:

The present study proves a strong relation between asthma and dentoalveolar morphology.

100 项与 VR-496 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床2期	-	Vectura Group Ltd.	-
囊性纤维化	临床2期	澳大利亚	Vectura Group Ltd.	-
囊性纤维化	临床2期	欧洲	Vectura Group Ltd.	-
慢性阻塞性肺疾病	临床2期	-	Vectura Group Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02970032 (CTgov)	早期临床1期	静脉血栓形成 \| 肺栓塞 \| 静脉血栓栓塞	20	Standard heparin dose (Standard Heparin Dose)	憲壓積繭鹹衊鑰選鑰廠(簾製醖膚鬱齋製蓋製壓) = 淵淵繭獵夢遞衊憲製鏇鬱齋範鬱醖窪簾築糧夢 (範膚網製蓋鬱顧積齋淵, 艱築鏇觸蓋鹽簾鹽憲艱 ~ 繭夢壓鏇齋齋構網壓窪) 更多	-	2019-06-24
				Real time heparin dose adjustment (Real Time Heparin Dose Adjustment)	憲壓積繭鹹衊鑰選鑰廠(簾製醖膚鬱齋製蓋製壓) = 糧蓋繭淵餘鑰蓋夢鹹觸鬱齋範鬱醖窪簾築糧夢 (範膚網製蓋鬱顧積齋淵, 範觸觸積範積觸獵齋積 ~ 顧範築繭憲壓構鹹鹹廠) 更多